Read more about Indices see positive start; breadth strong on Business Standard. Key benchmark indices are trading higher in early trade on buying demand in index pivotals. At 9:25 IST, the barometer index, the S&P BSE Sensex, was up 47.12 points or 0.1% at 48,724.67. The Nifty 50 index was up 28.30 points or 0.19% at
Cipla rose 1.10% to Rs 898.50 after the drug major said it will distribute Roche s antibody cocktail (Casirivimab and Imdevimab) in India.
Roche India said that the Central Drugs Standards Control Organisation (CDSCO) has provided an Emergency Use Authorisation (EUA) for Roche s antibody cocktail (Casirivimab and Imdevimab) in India. The approval was based on the data that have been filed for the EUA in the United States, and the scientific opinion of the Committee for Medicinal Products for Human Use (CHMP) in the European Union.
The antibody cocktail is to be administered for the treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age or older, weighing at least 40 kg) who are confirmed to be infected with SARS-COV2 and who are at high risk of developing severe COVID-19 disease.
Last Updated:
India Approves Roche s Antibody Cocktail COVID Treatment For Mild Cases; Trump Had Taken
The Central Drugs Standards Control Organisation (CDSCO) on Wednesday granted Emergency Use Authorisation (EUA) to Roche for the antibody cocktail.
Expanding its arsenal of drugs to battle the massive second wave of COVID-19, the Central Drugs Standards Control Organisation (CDSCO) on Wednesday granted Emergency Use Authorisation (EUA) to Swiss pharma company Roche for the antibody cocktail Casirivimab and Imdevimab in India. The decision was taken based on data filed with the U.S. regulators and the scientific opinion of a European regulatory panel.
Confirming the news, Roche Pharma India MD V Simpson Emmanuel said, With the increasing number of COVID-19 infections in India, Roche is committed to doing everything we can to minimize hospitalizations and ease pressure on healthcare systems, He added, This is where neutralizing antibody cocktails like Casirivima
Here are the top stocks that are likely to sway the markets today:
Results today: A total of 25 firms are slated to post their March quarter numbers today, including Hero MotoCorp, Tata Consumer, Adani Power, Blue Star, Hikal, Icra and Raymond.
HeroMoto Corp, slated to report its March quarter results (Q4FY21) on May 6, is expected to post nearly 60 per cent year-on-year growth in earnings before interest, tax, depreciation, and amortization (Ebitda) aided by healthy sales volume and low base effect. However, price hikes taken due to BS-VI transition and to off-set increase in input costs may not be enough to cushion Ebitda margin hit, say analysts.
India approves Roche s antibody cocktail to treat COVID-19; Cipla to distribute the drug
The approval was granted by the Central Drugs Standards Control Organisation (CDSO) basis data filed with the US regulators as well as the scientific opinion of a European regulatory panel
BusinessToday.In | May 6, 2021 | Updated 09:53 IST
A logo of Swiss pharmaceutical company Roche in Rotkreuz, Switzerland, April 12, 2012. (Photo: Reuters)
Pharma giant Roche India has received the Emergency Use Authorisation (EUA) for a COVID-19 antibody-drug cocktail Casirivimab and Imdevimab in the country for the treatment of coronavirus patients. The drug cocktail is developed by Roche and Regeneron.
The approval was granted by the Central Drugs Standards Control Organisation (CDSCO) basis data filed with the US regulators as well as the scientific opinion of a European regulatory panel. This will further expand India s arsenal of drugs to fight a massive second wave of COVID-19.